CANbridge Pharmaceuticals Inc.

CANbridge Pharmaceuticals Inc is a China-based company mainly engaged in the research, development and commercialization of rare disease treatments. The Company's main businesses are the development, production, promotion and sales of medical products. The Company's main product is the glycosylated fusion protein CAN008 for the treatment of glioblastoma (GBM). The Company's products are mainly used in rare diseases such as Hunter's syndrome (MPS II), rare tumors and other fields. The Company is also engaged in the development of gene therapy.